Better CEO Sues Founder Vishal Garg Over 'Poison Pill'

Better CEO Vishal Garg has filed a lawsuit against the company's founder, also named Vishal Garg, alleging the improper implementation of a 'poison pill' provision. This legal action, initiated on May 29, 2024, follows closely on the heels of Better suing its founder for allegedly engaging in unlawful solicitation of stockholders. The 'poison pill,' officially known as a shareholder rights plan, is a defensive tactic used by companies to prevent hostile takeovers. In this instance, the provision is reportedly designed to dilute the voting power of any entity that acquires a significant stake in Better without board approval. The lawsuit contends that the founder, Vishal Garg, acted unilaterally and without proper authorization from the board of directors to enact this measure. This move is seen as a direct response to the founder's alleged attempts to regain control or influence over the company he established. The legal dispute highlights a significant internal conflict within Better, a digital mortgage lender that has faced its share of turbulence since its inception. The company has been working to stabilize its operations and financial standing, particularly after a period of rapid growth and subsequent challenges. The ongoing litigation between the current CEO and the founder introduces further uncertainty and potential disruption to these efforts. Better, which went public via a SPAC merger in August 2021, has been navigating a complex market environment. The company's financial performance and strategic direction have been under scrutiny, making internal stability crucial. The founder's alleged solicitation of stockholders suggests an effort to rally support for his agenda, potentially challenging the current leadership's strategy. The 'poison pill' mechanism, if deemed valid, would serve as a significant barrier to any such attempts by the founder to increase his stake or influence through stock acquisition. The court's decision on the validity and implementation of this provision will be critical in shaping the future power dynamics at Better. The company's board of directors is expected to be a key focus in the legal proceedings, as the authorization and oversight of such defensive measures typically fall under their purview. The lawsuit aims to have the 'poison pill' declared invalid and unenforceable, thereby removing a significant obstacle for any potential future actions by the founder or other stakeholders. This legal battle underscores the intense governance and control issues that can arise within rapidly growing companies, especially when founders and current management diverge on strategic direction and control. The outcome could have substantial implications for Better's corporate governance, its ability to attract future investment, and its overall market position.